scholarly article | Q13442814 |
P2860 | cites work | Association of trypanolytic ApoL1 variants with kidney disease in African Americans | Q24606581 |
Supramaximal dose of candesartan in proteinuric renal disease | Q24649685 | ||
The role of diastolic blood pressure when treating isolated systolic hypertension | Q28145536 | ||
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE> | Q28204197 | ||
Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee | Q28303699 | ||
Late escape from the antiproteinuric effect of ace inhibitors in nondiabetic renal disease | Q32066990 | ||
Morbidity and Mortality of Orthostatic Hypotension: Implications for Management of Cardiovascular Disease | Q33159154 | ||
Blood pressure and survival in the oldest old. | Q33277116 | ||
United States Renal Data System 2008 Annual Data Report | Q33396108 | ||
Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. | Q33414957 | ||
Long term monitoring in patients receiving treatment to lower blood pressure: analysis of data from placebo controlled randomised controlled trial | Q33437564 | ||
Use and interpretation of ambulatory blood pressure monitoring: recommendations of the British hypertension society | Q33816876 | ||
Efficacy and safety of benazepril for advanced chronic renal insufficiency | Q33992851 | ||
Effects of intensive blood-pressure control in type 2 diabetes mellitus | Q34008161 | ||
Outcomes Among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy | Q34396234 | ||
Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy | Q34432806 | ||
Population-based study on the prevalence and correlates of orthostatic hypotension/hypertension and orthostatic dizziness | Q34810442 | ||
initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial | Q35179914 | ||
Arterial stiffness in renal patients: an update | Q36163632 | ||
Ambulatory blood-pressure monitoring | Q36493993 | ||
Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan | Q36662162 | ||
The incidence and implications of aldosterone breakthrough | Q36918649 | ||
Late onset azotemia from RAAS blockade in CKD patients with normal renal arteries and no precipitating risk factors | Q37057985 | ||
Hypertension-associated kidney disease: perhaps no more | Q37299028 | ||
Susceptibility genes in common complex kidney disease | Q37616991 | ||
The angiotensin II type 2 receptor in cardiovascular disease | Q37622575 | ||
Home sphygmomanometers: what should a nephrologist know? | Q37741119 | ||
European Society of Hypertension practice guidelines for home blood pressure monitoring. | Q37762443 | ||
Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement | Q37797817 | ||
The conundrum of increased burden of end-stage renal disease in Asians | Q38411892 | ||
Acute fall in glomerular filtration rate with renin-angiotensin system inhibition: a biomeasure of therapeutic success? | Q39728537 | ||
Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study | Q39972761 | ||
Increased pulse wave velocity is associated with low creatinine clearance and proteinuria in a screened cohort | Q40331970 | ||
Strict blood-pressure control and progression of renal failure in children | Q43257210 | ||
Creatinine clearance, pulse wave velocity, carotid compliance and essential hypertension | Q43586133 | ||
Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk | Q43759322 | ||
Determinants of accelerated progression of arterial stiffness in normotensive subjects and in treated hypertensive subjects over a 6-year period | Q43913695 | ||
A low-sodium diet potentiates the effects of losartan in type 2 diabetes | Q43937012 | ||
Blood pressure and decline in kidney function: findings from the Systolic Hypertension in the Elderly Program (SHEP). | Q44192009 | ||
Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study | Q44511770 | ||
Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results | Q45173409 | ||
Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents | Q45198988 | ||
Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study | Q45204771 | ||
Blood pressure control in chronic kidney disease: is less really more? | Q45432316 | ||
Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design | Q46162422 | ||
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 | ||
Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial | Q46522431 | ||
Aliskiren combined with losartan in type 2 diabetes and nephropathy | Q46558669 | ||
Association of low blood pressure with increased mortality in patients with moderate to severe chronic kidney disease | Q46900011 | ||
Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension | Q48267169 | ||
Arterial structure and function in end-stage renal disease | Q48713931 | ||
Adherence to antihypertensive agents and blood pressure control in chronic kidney disease | Q48971003 | ||
Lowest systolic blood pressure is associated with stroke in stages 3 to 4 chronic kidney disease | Q50176457 | ||
Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Associati | Q51542873 | ||
Jananese Society of Hypertension (JSH) Guidelines for Self-Monitoring of Blood Pressure at Home | Q51797042 | ||
Association of impaired diurnal blood pressure variation with a subsequent decline in glomerular filtration rate. | Q51943135 | ||
The enigma of hypertensive ESRD: observations on incidence and trends in 18 European, Canadian, and Asian-Pacific populations, 1998 to 2002 | Q53007477 | ||
Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? | Q53253898 | ||
Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. | Q54348402 | ||
Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement | Q57085541 | ||
Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE) | Q57396207 | ||
ACE-inhibitor use and the long-term risk of renal failure in diabetes | Q57446641 | ||
Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic Nephropathy: Post Hoc Analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Trial | Q57702534 | ||
Diastolic Blood Pressure and Mortality in the Elderly With Cardiovascular Disease | Q60594035 | ||
Is Doubling of Serum Creatinine a Valid Clinical ‘Hard’ Endpoint in Clinical Nephrology Trials | Q61873319 | ||
The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide | Q74816907 | ||
Blood pressure recordings within and outside the clinic and cardiovascular events in chronic kidney disease | Q79379738 | ||
Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency | Q80313261 | ||
Stiffness of capacitive and conduit arteries: prognostic significance for end-stage renal disease patients | Q81489212 | ||
Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease | Q81555894 | ||
Home blood pressure monitoring in CKD | Q81853685 | ||
Prognostic importance of clinic and home blood pressure recordings in patients with chronic kidney disease | Q82242344 | ||
Blood pressure control in CKD patients: why do we fail to implement the guidelines? | Q83062895 | ||
Geographic, ethnic, age-related and temporal variation in the incidence of end-stage renal disease in Europe, Canada and the Asia-Pacific region, 1998-2002 | Q83089797 | ||
ONTARGET still OFF-TARGET? | Q83491265 | ||
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function | Q83751680 | ||
Renal Association Clinical Practice Guideline on detection, monitoring and management of patients with CKD | Q84069692 | ||
Prognostic role of ambulatory blood pressure measurement in patients with nondialysis chronic kidney disease | Q84456381 | ||
The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease | Q84699464 | ||
Ambulatory blood pressure monitoring | Q94210258 | ||
P433 | issue | 5 | |
P304 | page(s) | 382-387 | |
P577 | publication date | 2012-12-01 | |
P1433 | published in | Kidney International Supplements | Q26842881 |
P1476 | title | Chapter 8: Future directions and controversies | |
P478 | volume | 2 |